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ISSObjective: To describe the pharmacokinetics of tenofovir and emtricitabine in the third
trimester of pregnant HIV-infected women and at postpartum.
Design: A nonrandomized, open-label, multicentre phase IV study in HIV-infected
pregnant women recruited from HIV treatment centres in Europe.
Methods: HIV-infected pregnant women treated with the nucleotide/nucleoside
analogue reverse transcriptase inhibitors (NRTIs) tenofovir disoproxil fumarate (TDF
300 mg; equivalent to 245 mg tenofovir disoproxil) and/or emtricitabine (FTC 200 mg)
were included in the study. Twenty-four-hour pharmacokinetic curves were recorded in
the third trimester (preferably week 33) and postpartum (preferably week 4–6).
Collection of a cord blood sample and maternal sample at delivery was optional.
Pharmacokinetic parameters were calculated using WinNonlin software version 5.3.
Statistical analysis was conducted using SPSS version 16.0.
Results: Thirty-four women were included in the analysis. Geometric mean ratios of
third trimester vs. postpartum [90% confidence interval (CI)] were 0.77 (0.71–0.83) for
TDF area under the curve (AUC0–24 h); 0.81 (0.68–0.96) for TDF Cmax and 0.79 (0.70–
0.90) for TDF C24 h and 0.75 (0.68–0.82) for FTC AUC0–24 h; and 0.87 (0.77–0.99) for
FTC Cmax and 0.77 (0.52–1.12) for FTC C24 h. The viral load close to delivery was less
than 200 copies/ml in all but one patient, the average gestational age at delivery was 38
weeks. All children were tested HIV-negative and no congenital abnormalities were
reported.
Conclusion: Although pharmacokinetic exposure of the NRTIs TDF and FTC during
pregnancy is approximately 25% lower, this was not associated with virological failure
in this study and did not result in mother-to-child transmission.
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740 AIDS 2013, Vol 27 No 5IntroductionIn 2010, approximately 17.5 million women were
infected with HIV, most of who were of child-bearing
age [1]. It is estimated that 39% of the European women
infected with HIV have a desire for childbearing in the
future, which is comparable to HIV-uninfected women
[2]. This has also been reported for women infected with
HIV in the USA [3] and South Africa [4].
Combination antiretroviral therapy (cART) has been
shown to be a highly effective strategy for preventing
mother-to-child transmission (PMTCT) of HIV, reducing
the risk from 15–40 to less than 2% [5]. The US
Department of Health and Human Services guidelines
recommend the inclusion of one or more nucleoside
analogue reverse transcriptase inhibitors (NRTIs) with
good transplacental passage in the cART regimen, when
feasible [6]. The most commonly used NRTIs are
zidovudine (ZDV) and lamivudine (3TC), mainly because
of the vastly greater clinical experience with these
compounds during pregnancy. However, an overview of
antiretroviral drugs prescribed during pregnancy between
1995 and 2009 showed an increase in the use of tenofovir
disoproxil (TDF)/emtricitabine (FTC) to approximately
30%, whereas the use of ZDV/3TC decreased from
approximately 90 to 70% [7]. This reflects the recom-
mendations for first-line NRTI backbone (TDF/FTC
combination) in nonpregnant adults [8]. All four NRTIs
cross the placenta well [9–14]. The current summary of
product characteristics of Truvada [15] states that its usemay
be considered during pregnancy, if necessary. Safety issues
on the use of antiretrovirals during pregnancy concern
exposure of the mother, influence on pregnancy duration
and teratogenicity. cARTuse (especially protease inhibitor
based) during pregnancy has been reported to be associated
with an increased rate of preterm delivery (<37 weeks
gestational age) in European studies [16]. Most North
American studies have not shown this association [17,18].
The antiretroviral pregnancy registry interim report (up
to 31 January 2012) did not detect a two-fold increase in
the risk of overall birth defects: the prevalence of birth
defects of both TDF and FTC was 2.3% [19], compared
with 2.1% prevalence of major birth defects in the
European general population [20]. Two individual cases
of pyelectasis in children born from mothers receiving
TDF-containing therapy during pregnancy have been
described [21]. In a macaque model, perinatal exposure to
very high doses of TDF resulted in bone toxicity in some
offspring [22]. This has not yet been reported in humans
[23,24], nor in another macaque model [25]. In studies
with FTC during pregnancy, no FTC-related congenital
anomalies were reported [26,27] and FTC animal studies
do not indicate reproductive toxicity [28].
Human physiology alters during pregnancy, potentially
affecting the pharmacokinetics of drugs [29–31],pyright © Lippincott Williams & Wilkins. Unauthomostly resulting in lower exposure of medication
during pregnancy.
Pharmacokinetic parameters of chronic exposure to
tenofovir (TFV) during pregnancy have been presented as
abstracts at conferences only. It was concluded that
exposure during pregnancy is lower, but with area under
the curves (AUCs) not below the 10th percentile of
nonpregnant patients (2 mg  h/l) for most women [10].
In studies of single-dose TDF given for HIV PMTCT at
onset of labour, doses of 600 and 900 mg TDF, which are
higher than that for chronic administration (300 mg),
have been used [14,27]. For the 600 mg dose, plasma
concentrations were similar to those observed after
chronic administration of 300 mg TDF in nonpregnant
adults [12,14] and with an initial dose of 600 mg TDF in
nonpregnant adults [11]. A population study of 186
women (of whom 46 were pregnant), with a sparse
sampling method, showed 39% higher apparent clearance
of TFV in the pregnant women [32].
Pharmacokinetic parameters of chronic exposure to FTC
have been reported as lower during pregnancy, but the
magnitude of the decrease appears to be small, 10% [33] to
18% [26]. When 400 mg is administered at labour
initiation, the plasma concentrations appear higher than
after chronic administration of 200 mg FTC in non-
pregnant adults [34].
As information on pharmacokinetic changes during
pregnancy is limited (especially for chronic use during
pregnancy) and the use of TDF and FTC during
pregnancy is increasing, we studied the effect of
pregnancy on TFV and FTC pharmacokinetics.Methods
This was a nonrandomized, open-label, multicentre phase
IV study in HIV-infected pregnant women recruited
from HIV treatment centres in Europe (PANNA
network: www.pannastudy.com). The PANNA network
is a European network of hospitals collecting pharma-
cokinetic curves of several antiretroviral drugs during
pregnancy in a prospective study. In total, 17 hospitals are
involved in the network, data in this publication were
collected from 10 hospitals between November 2008 and
January 2012.
The study was conducted in compliance with the
principles of the ‘Declaration of Helsinki’. Informed
consent was obtained from each participant before
entering the study. The study was approved by the
medical ethical committee from each individual centre
involved and by the national authorities if applicable. The
study was registered at ClinicalTrials.gov under
number NCT00825929.rized reproduction of this article is prohibited.
Tenofovir and emtricitabine in pregnancy Colbers et al. 741Patient eligibility included being HIV infected, pregnant,
at least 18 years of age at screening and treated with a
cARTregimen containing TDF and/or FTC for at least 2
weeks before the day of first pharmacokinetic curve
evaluation (in the third trimester of pregnancy). Patients
were excluded if they had a past medical history or current
condition that might interfere with drug absorption,
distribution, metabolism or excretion (such as renal
failure or hepatic failure) or presented with grade III/IV
anaemia (i.e. haemoglobin <4.6 mmol/l or <7.4 g/dl)
at screening.
Safety assessments and viral load
Inclusion screening consisted of medical history, physical
examination, serum biochemistry, haematology and
qualitative urinalysis, HIV-1 RNA load and CD4 cell
count. Analyses for safety assessments were performed by
local laboratories. Blood samples for safety assessments
were further taken at the visits for pharmacokinetic blood
sampling and at delivery (if they delivered at the hospital).
Patients were asked for adverse events at each visit, the
DAIDS toxicity table (2004) was used to grade the
reported adverse events. The HIV-status of the infants
was collected.
Pharmacokinetic blood sampling
A 24-h pharmacokinetic curve was recorded after at least
2 weeks of TDF and/or FTC treatment during the third
trimester (preferably at week 33) and at least 2 weeks
postpartum (preferably 4–6 weeks postpartum). At
delivery (if possible), a cord blood sample and a blood
sample from the mother were taken. Concentrations of
TFVand FTC in plasma were analysed by the laboratory
of the Pharmacy of the Radboud University Nijmegen
Medical Centre.
A standard breakfast (650 kcal; 30 g fat) was served prior
to (observed) dosing on the pharmacokinetic days. Six
millilitre of blood was collected just before drug intake
(predose) and at 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 h after
medication intake (10 samples) at all pharmacokinetic
study days. Plasma was separated and stored at 188C or
lower until shipment on dry ice to the central laboratory
for analysis.
Analytical and pharmacokinetic methods
Concentrations of TFVand FTC in plasma were analysed
by use of a validated reversed phase high-pressure liquid
chromatography method with fluorescence detection.
Sample preparation for TFV consisted of a liquid–liquid
extraction. The solution was injected onto a Symmetry
Shield RP 18 column (3.5 mm, 150 mm 4.6 mm). The
flow rate was set at 1.0 ml/min and TFV was detected
using a fluorescence detector (lexcitation¼ 232 nm,
lemission¼ 420 nm). TFV lower limit of quantification
(LOQ) was 0.015 mg/l. The linear calibration ranges in
plasma were 0.015–1.5 mg/l.Copyright © Lippincott Williams & Wilkins. UnautSample preparation for FTC consisted of a solid-phase
extraction. One hundred and ninety microlitres of the
solution was injected onto an Atlantis CP18 column
(5 mm, 150 mm 4.6 mm). The flow rate was set at
1.0 ml/min. FTC was detected using a fluorescence
detector (lexcitation¼ 244 nm, lemission¼ 356 nm). FTC
LOQ was 0.030 mg/l. The linear calibration ranges in
plasma were 0.03–5.0 mg/l. The assays were externally
validated through ACTG [35].
Pharmacokinetic parameters were determined using a
noncompartmental model in WinNonlin version 5.3
(Pharsight Corporation, Sunnyvale, California, USA).
Area under the curve (AUC0–24 h) using the trapezoidal
rule, the trough concentration (C24 h) defined as the
sample taken at time point 24 h (or extrapolated if the
sample was missing), maximum concentration (Cmax),
elimination half-life (Thalf), time of maximum concen-
tration (Tmax) and apparent clearance (CL/F, being the
dose/AUC0–24 h) were determined per individual curve.
Statistical analysis data handling
Patients for whom a curve was taken during pregnancy
were included in demographic, safety analyses and
descriptive statistics of the pharmacokinetic parameters.
Geometric mean ratios (GMRs) were calculated for the
patients with a curve in the third trimester and a
postpartum curve. Pharmacokinetic parameters are
reported as geometric means with 95% CIs. GMRs of
AUC0–24 h, Cmax, C24 h, CL/F and Thalf of third trimester
vs. postpartum were calculated. To indicate whether the
pharmacokinetic parameters during pregnancy differed
statistically significantly from the postpartum parameters,
a paired t-test was performed on the log-transformed
parameters. Cord blood : maternal blood concentration
ratios were determined and described.Results
Thirty-four patients receiving TDF and/or FTC during
pregnancy from 10 different sites from the PANNA
network were enrolled in the study. The characteristics of
the patients and pregnancy outcome are depicted in Table
1. Sixteen patients were white, 17 were black and one was
of mixed race. Eleven (32%) patients were treatment naive
at conception and 23 were already on cART before
pregnancy. Thirty-one out of 34 patients used Truvada.
Other NRTIs used were zidovudine (n¼ 2) and
lamivudine (n¼ 1). Twenty-four of the patients were
on a boosted protease inhibitor based cART, six were on a
nonnucleoside reverse transcriptase inhibitor (NNRTI)-
based cART, four were on the integrase inhibitor
raltegravir, one was on raltegravirþ protease inhibitor
and one was on maravirocþ protease inhibitor. No other
concomitant medication was used which could possibly
influence TFV or FTC exposure.horized reproduction of this article is prohibited.
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Table 1. Patient characteristics.





Smoking [n (%)] 7 (21)
Alcohol use [n (%)] 4 (12)
Truvada use [n (%)] 31 (91)
Treatment naive at start of pregnancy [n (%)] 11 (32)
ARV treatment duration before pregnancy [months, median (range)] 50 (2–135)
Concomitant ARVs [n (%)]
Protease inhibitors 24 (71) (11 atazanavir/r, 10 darunavir/r, 2 lopinavir/r,
2 saquinavir/r, 1 fosamprenavir/r)





Gestational age [weeks, median (range)] 33 (28–38)
Weight [kg, median (range)] 75 (49–123)
HIV-RNA undetectable <50 [n (%)] 28 (83) /<200: 33 (97)
CD4 cell count [cells/ml, median (range)] 545 (120–1333)
Creatinine concentration [mmol/l, median (range)] 54 (33–71)
Creatinine clearance (Cockcroft) [ml/min, median (range)] 171 (110–292)
Postpartum (N¼28)
Time after delivery [weeks, median (range)] 5 (3–9)
Weight [kg, median (range)] 70 (43–114)
HIV-RNA undetectable <50 [n (%)] 23 (82) /<200: 28 (100)
CD4 cell count [cells/ml, median (range)] 588 (130–1210)
Creatinine concentration [mmol/l, median (range)] 67 (50–86)
Creatinine clearance (Cockcroft) [ml/min, median (range)] 124 (82–190)
Pregnancy outcomes (N¼34)
Gestational age [weeks, median (range)] 38 (36–41)
Caesarean section [n (%)] 20 (65): 3 unknown
Birth weight [g, median (range)] 3070 (2190–4350)
Infant VL undetectable [n (%)]a 34 (100)
ARV, antiretroviral; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; VL, viral load.
aHIV-DNA PCR test.A total of 34 TFV curves were collected in the third
trimester (median 3 weeks gestational age) and 27 curves
postpartum (median 5 weeks postpartum). For FTC, a
total of 27 curves were collected in the third trimester and
24 postpartum. For four patients who had been treated
with TDF and FTC, insufficient plasma remained to
determine the FTC concentrations. Seven patients did
not have a postpartum curve due to several reasons:




























Fig. 1. Mean concentration–time profiles.changed medication (n¼ 1), and insufficient plasma for
analysis (n¼ 1).
Pharmacokinetics
The mean plasma concentration–time profiles of TFV
and FTC in the third trimester and postpartum are
presented in Fig. 1; summary statistics of the pharma-
cokinetic parameters are listed in Table 2. The
AUC0–24 h, Cmax, C24 h of TFV were, respectively, 23,rized reproduction of this article is prohibited.
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Table 2. Pharmacokinetic parameters.
Third trimestera Postpartuma GM ratio (90% CI) of third
trimester : postpartum
Pb
Tenofovir n¼34 n¼27 n¼27
AUC0–24 h (mg h/l) 2.46 (2.23–2.66) 3.17 (2.86–3.52) 0.77 (0.71–0.83) <0.001
Cmax (mg/l) 0.28 (0.24–0.31) 0.33 (0.29–0.39) 0.81 (0.74–0.89) 0.001
Tmax (h) 1.0 (0.5–4.0) 1.1 (0.5–4.0)
Cpredose (mg/l) 0.049 (0.043–0.056) 0.060 (0.050–0.073) 0.81 (0.68–0.96)
C24 h (mg/l) 0.052 (0.047–0.059) 0.066 (0.058–0.076) 0.79 (0.70–0.90) 0.003
Thalf (h) 15 (14–16) 15 (13–17) 1.00 (0.87–1.15) 0.987
CLss/F (l/h) 55 (51–61) 43 (39–48) 1.30 (1.20–1.40) <0.001
Emtricitabine n¼27 n¼24 n¼24
AUC0–24 h (mg h/l) 9.56 (8.99–10.48) 13.0 (11.8–14.3) 0.75 (0.68–0.82) <0.001
Cmax (mg/l) 1.79 (1.57–1.99) 2.02 (1.78–2.30) 0.87 (0.77–0.99) 0.048
Tmax (h) 2.0 (0.5–4.0) 2.0 (1.0–6.0)
Cpredose (mg/l) 0.057 (0.051–0.084) 0.115 (0.088–0.150) 0.57 (0.44–0.73)
C24 h (mg/l) 0.052 (0.043–0.073) 0.073 (0.054–0.098) 0.77 (0.52–1.12) 0.232
Thalf (h) 6 (5–7) 6 (5–6) 1.05 (0.91–1.21) 0.570
CLss/F (l/h) 21 (19–22) 15 (14–17) 1.34 (1.22–1.47) <0.001
AUC, area under the curve; CI, confidence interval; GM, geometric mean.
aAll values are GM (95% CI) except for Tmax [median (minimum–maximum)].
bPaired t-test on log-transformed data.19 and 21% lower during pregnancy compared with
postpartum (intrasubject comparison). For FTC, the
AUC0–24 h, Cmax, C24 h were 25, 13 and 23% lower,
respectively. For both compounds, the CLss/F is increased
during pregnancy (30 and 34% increased for TFVand FTC,
respectively), whereas the Thalf was not affected. The paired
samples t-test revealed a significant difference for TFVand
FTC AUC0–24 h, Cmax and CLss/F as well as TFV C24 h
between the third trimester and postpartum.
In Fig. 2, the individual AUC0–24 h for TFV and FTC
during the third trimester and postpartum are depicted; a
subdivision was made for the concomitant use of
NNRTI, protease inhibitor and/or integrase inhibitor.
No difference between the different cART regimens was


























____ Protease inhibitor-based cART
- - - -  Nonnucleoside reverse transcriptase inhibitor-b
. _ . _ Integrase inhibitor-based cART
......... Entry inhibitor + Protease inhibitor-based cART
Fig. 2. Individual area under the curve plot.Sixteen umbilical cord blood samples were collected with
matching maternal blood samples. In one cord blood
sample (and the matching maternal sample), FTC/TFV
concentrations were undetectable. The median time
between the reported last dose and delivery was 8.5 h
(range 0–32 h) and the median time between cord blood
sample and maternal sample was 3 min (0–75 min). The
median (range) ratio of cord blood : maternal blood was
0.82 (0.64–1.10; n¼ 14) for TFV and 1.63 (0.46–1.82;
n¼ 10) for FTC.
Efficacy and safety
HIV viral load close to delivery (median 34 weeks
gestational age) was detectable in seven women
(72–272 copies/ml). The average gestational age at






























744 AIDS 2013, Vol 27 No 5tested HIV-negative and no congenital abnormalities
were reported. Four of the infants (12%) were born
between 36 and 37 weeks gestational age. Three babies
had a low birth weight (<2500 g).
Three patients developed a serious adverse event (SAE).
One patient had a hospital admission because she thought
the baby was not moving, the baby was born without
problems (36.5 weeks gestational age); one patient had a
transfusion with packed cells to treat anaemia 24 h
postpartum, anaemia was attributed to blood loss during/
after delivery; and one patient had a postnatal uterus
atony, coagulation problems and massive blood loss. All
patients recovered. These SAEs were judged by the local
investigator not to be related to the cART given. Nine
other patients reported adverse events, all were grade 1 or
2 and not or unlikely related to the cART given. These
adverse events included back pain, oesophagus pain,
inflammation of right eye, urinary tract infection,
common cold, gestational diabetes, blood loss during
pregnancy, vomiting and nausea; anaemia (2), bronchitis,
infection to caesarean section wound, 400 ml blood loss at
vaginal delivery and coryza.
Creatinine concentrations and glomerular filtration rate
(GFR; using the Cockroft–Gault formula) were deter-
mined in the third trimester and postpartum (see Table 1).
During pregnancy, creatinine concentrations were lower
(median 54 vs. 67 mmol/l) and estimated GFR higher
(171 vs. 124 ml/min) compared with postpartum.
Pharmacokinetics–efficacy relationship
HIV viral loads were detectable (>50 copies/ml) for
seven patients around delivery. Five out of the seven
patients with a detectable viral load were on cART before
pregnancy (one on NNRTI-based cART and four on
protease inhibitor-based cART) and two started treat-
ment during pregnancy (protease inhibitor-based cART);
the treatment duration was 24 and 28 weeks at delivery
for these latter two patients. Adherence was checked by
asking whether the patients had been taking their












































AUC UD AUC DET Cmax UD Cmax DET C24h UD C24h DET
Fig. 3. Comparison of individual pharmacokinetic parameters f
delivery. AUC, area under the curve; DET, detectable viral load;before the measurement. All patients reported to have
been adherent to therapy during that period.
Third trimester TFV, geometric means (95% CI) for
AUC0–24 h were 2.39 (2.17–2.64) mg  h/l and 2.72
(2.03–3.65) mg  h/l for patients with undetectable and
detectable viral loads around delivery, respectively. For
third trimester FTC, geometric means (95% CI) for
AUC0–24 h were 9.41 (8.66–10.2) mg  h/l (patients with
undetectable viral load) and 10.08 (7.83–13.0) mg  h/l
(patients with detectable viral load). In Fig. 3, the
individual TFVand FTC AUC0–24 h, Cmax and C24 h are
depicted for patients who had a detectable viral load
around delivery compared with the patients who had an
undetectable viral load around delivery. For all these
parameters, the values are comparable between these
two groups.Discussion
In this study, we evaluated the pharmacokinetics of TFV
and FTC, in the majority of cases combined in Truvada,
in 34 pregnant HIV-infected patients, at the third
trimester of pregnancy and after delivery. In the third
trimester of pregnancy, a decrease in TFV AUC0–24 h,
Cmax and C24 h (23, 19 and 21%, respectively) was
observed as well as a decrease in FTC AUC0–24 h, Cmax
and C24 h (25, 13 and 23%, respectively). The clearance
(CLss/F) was markedly increased during pregnancy for
both compounds (TFV 30% and FTC 34%).
TFV and FTC are mainly excreted unchanged in urine,
indicating that renal clearance is the major route of
elimination. It is known that renal clearance is increased
during pregnancy [36], in line with our findings that
estimated creatinine clearance increased during preg-
nancy by around 40%. Although possibly influencing the
decreased exposure during pregnancy found in this study,
this was not translated into shorter half-life of TFV and
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Emtricitabine PK parameters
or patients with and without detectable viral load around
UD, undetectable viral load.
Tenofovir and emtricitabine in pregnancy Colbers et al. 745interval, which is possibly not a correct estimate, because
the last sample was taken 24 h after dosing, this means that
the entire elimination phase was not covered.
Other physiological changes during pregnancy are
reduced intestinal motility, increased gastric pH, a larger
plasma volume, increased hepatic blood flow, decreased
protein binding and induced hepatic enzymes. The Cmax
decreased by 19% for TFV and 13% for FTC, potentially
implying the influence of larger plasma volume and
possibly decreased gastrointestinal absorption. However,
the absorption was not delayed, as Tmax was similar during
and after pregnancy for both compounds.
Protease inhibitors are known to increase TFV concen-
trations [37]. In this study, the TFV AUC0–24 h for
patients on an NNRTI regimen are similar to these on a
protease inhibitor regimen. Possible explanations for this
finding could be a decrease in boosting effect during
pregnancy because of the lower exposure to protease
inhibitors during pregnancy [9,38,39]; furthermore, the
number of patients using a nonprotease inhibitor regimen
in this study was low (only 18%), reducing the power to
detect a difference.
There is no efficacy threshold level for TFV or FTC. In
previous studies with TDF, a threshold of 2 mg  h/l for
AUC0–24 h [6] (being the 10th percentile of nonpreg-
nant controls) was used and an AUC0–24 h threshold for
FTC of at least 7 mg  h/l (30% reduction from the
normal controls) [26]. Using these thresholds, the study
showed that 26% of the patients receiving TDF did not
meet the threshold in the third trimester compared with
only 4% of the patients in the postpartum period. For
the patients on FTC, only 4% did not meet the threshold
in the third trimester compared with 0% postpartum.
One of nine of patients with TFV AUC0–24 h below the
threshold had a detectable viral load around delivery,
compared with six of 25 with AUC0–24 h above the
threshold. This finding indicates that in this study, TFV
AUC0–24 h below the 10th percentile of nonpregnant
controls was not associated with virological failure of the
mother and did not result in mother-to-child trans-
mission (MTCT).
The reference tenofovir AUC in nonpregnant adults is
3.324 mg  h/l with a Cmax of 0.326 mg/l, a Cmin of
0.064 mg/l and a Thalf of 12–18 h [40–42]. The reference
emtricitabine AUC is 10.0 mg  h/l with a Cmax of
1.86 mg/l, a Cmin of 0.09 mg/l and a Thalf of 10 h [28].
The tenofovir and emtricitabine postpartum pharmaco-
kinetic parameters found in this study are in line with
reference values reported in the summary product
characteristics. This implies that pharmacokinetic
parameters recorded 5 weeks after delivery can be used
as reference values for the nonpregnant situation, that is
the pregnancy induced physiological changes were not
present anymore.Copyright © Lippincott Williams & Wilkins. UnautThe decreased FTC AUC and C24 h observed in this study
is in line with the decrease reported by Stek et al. [26].
However, we also observed a decrease in FTC Cmax,
which was not observed earlier.
For other NRTIs (zidovudine, lamivudine, didanosine
and abacavir), pharmacokinetic studies during pregnancy
also reported decreased exposure, without a need for dose
alteration [43–46].
For both compounds, placenta passage is good, concen-
trations in the cord blood are somewhat lower for TFV
and approximately similar to the concentrations of the
mother for FTC. This is in line with the findings of other
NRTIs [47]. In this review, cord blood : maternal ratios
for both compounds ranged from 0.60 to 1.6 (with an
outlier of 6.0 for tenofovir).
HIV viral load was undetectable (<50 copies/ml) for 79%
patients around delivery and less than 200 copies/ml for
97% of the patients. A possible explanation for the
detectable viral load could be shorter treatment duration
in these patients. The shortest treatment duration in these
patients was 24 weeks, which should be sufficient to
suppress the viral load, although both patients were on a
protease inhibitor based cART [48,49]. The third
trimester exposure to TFV and FTC was not lower in
patients with a detectable viral load (n¼ 7) compared
with the patients who had an undetectable viral load
around delivery.
None of the babies had a detectable HIV viral load and no
congenital abnormalities were reported. The adverse
events observed in this study were judged not be related to
the antiretroviral drugs taken but mainly to pregnancy.
Although the number of patients in this study is limited,
the safety information collected is extensive (safety
laboratory and adverse events were collected at each visit).
The safety information from this study suggests that the
use of Truvada during pregnancy seems to be safe. This
reflects the safety reporting on tenofovir use during
pregnancy [23,24,50].
None of the available formula for GFR is accurate during
pregnancy: the Cockroft–Gault (we used) overestimates
the GFR during pregnancy, because the increase in
weight is an increase in body water and fat but not in body
muscle mass [36]. The only reliable measure for GFR is
creatinine clearance by 24 h urine collection, but this
information was not collected in this study.
One of the strengths of this study is that it includes several
antiretroviral drugs in one study protocol. Patients using
these drugs as part of their cART can be included and
their treatment is not adapted for the study. Many patients
use more than one antiretroviral drug from the list of
medication to be investigated. Another advantage of the
study draws from the PANNA network itself and is thehorized reproduction of this article is prohibited.
Co
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available for investigation: approximately 50% white
European and 50% black patients were included.
A limitation of the study is that no pharmacokinetic curve
was collected in the second trimester. We focused on the
third trimester as drug disposition of antiretrovirals is
thought to be most affected during this period, because of
the prominent physiological changes present. Further-
more, in the phase close to delivery, maximum viral
suppression and antiretroviral effectiveness is considered
important in order to minimize MTCT. Subtherapeutic
concentrations in late pregnancy may have a negative
effect on antiviral efficacy. This is also a reason for
assessing drug exposure during the third trimester
of pregnancy.
In conclusion, although pharmacokinetic exposure of the
NRTIs TDF and FTC during pregnancy is approximately
25% lower, this was not associated with virological failure
in this study and did not result in MTCT.Acknowledgements
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